share_log

Immunic | 8-K: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic | 8-K: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis

Immunic | 8-K:Immunic宣佈Vidofludimus鈣治療複發性多發性硬化症第三階段ENSURE計劃中期分析取得積極成果
美股SEC公告 ·  10/22 03:48
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息